Positrigo AG
- Industry
- Medical Device
- Founded Year
- 2018
- Headquarters
- Technoparkstrasse 1, Zeppelin Wing, 5th Floor, Office 5009-5010, 8005 Zurich, Switzerland
- Employee Count
- 27
Key People
- Dr. Jannis Fischer - Founder & CEO
- Dr. Max Ahnen - Founder & COO
- Dr. Stefan Bircher - CCO
- Dr. Ilaria Sacco - CTO
- Ron Lissak - EVP & GM Positrigo Inc.
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises first-time entrepreneurs with over a decade of experience in their respective fields.
The founders and key executives have substantial experience in medical imaging and business development, which is advantageous for the company's growth.
- Clinical Need
-
Aspect: Very Strong
Summary: There is a significant unmet need for accessible and cost-effective brain imaging solutions, especially for early Alzheimer's detection.
With the global rise in Alzheimer's cases, affordable and early diagnostic tools like NeuroLF are essential for timely intervention and treatment planning.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has existing players, but Positrigo's unique value proposition differentiates it.
Traditional PET systems are larger and more expensive. Positrigo's NeuroLF offers a more accessible alternative, though market penetration will require strategic efforts.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a compact PET system presents moderate technical challenges.
The successful development and regulatory approval of NeuroLF indicate that technical hurdles have been effectively addressed.
- Patent
-
Aspect: Strong
Summary: Positrigo holds strong patents protecting its innovative technology.
The company's patents safeguard its unique approach to brain PET imaging, providing a barrier to entry for competitors.
- Financing
-
Aspect: Well-funded
Summary: Positrigo has secured substantial funding from reputable investors.
Investments from firms like HealthCap and Navivo Capital provide the financial resources needed for production scaling and market expansion.
- Regulatory
-
Aspect: 510k/PMA
Summary: NeuroLF has obtained both FDA clearance and CE mark approval.
Achieving these approvals demonstrates compliance with stringent standards, enabling sales in major markets.
Opportunity Rollup
- Odds of Success
- 4
- Peak Market Share
- 5.7
- Segment CAGR
- 4.9%
- Market Segment
- Diagnostic Imaging
- Market Sub Segment
- Neurology Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.86 |
| 3 | 2.00 |
| 4 | 3.99 |
| 5 | 5.70 |
Key Takeaway
Positrigo's innovative NeuroLF system addresses a critical need in early Alzheimer's diagnosis, supported by strong funding and regulatory approvals, positioning the company for significant market impact.